Globe on Big Pharma R&D Failure
3 Comments
Law Bytes
Episode 73: The Broadcasting Act Blunder – Why Minister Guilbeault is Wrong
November 30, 2020
Search Results placeholder
Recent Posts
The Broadcasting Act Blunder, Day 20: The Case Against Bill C-10 
The Broadcasting Act Blunder, Day 19: The Misleading Comparison to the European Union 
The Broadcasting Act Blunder, Day 18: The USMCA Trade Threat That Could Lead to Billions in Retaliatory Tariffs 
The Broadcasting Act Blunder, Day 17: The Uncertain Policy Directive 
The Law Bytes Podcast, Episode 73: The Broadcasting Act Blunder – Why Minister Guilbeault is Wrong
So, repeal C-22
If the drug companies can renege, then so can the goodies that were given to them be taken away.
Seems pretty straightforward to me.
Why aren’t there such things as charitable venture capital orgs? After-all many charities (eg JDRC) contribute to for-profit orgs. It seems to me that charitable donations would go much further if the beneficiaries of donations (R&D orgs) had to contribute returns back to charities. The role of charities like JDRC then would be to encourage R&D firms to take greater risks.
Hey, Michael! Don’t be so ungrateful or narrow minded. What about the bevy of busy lawyers who make gazillions every year doing “research” on their endless litany of pharmaceutical patent cases in the courts? What about all that useful literature and education directed at the medical profession, so that they are better informed about what pills their patients should pop? That takes a lot of “research and development”. And what about all the consumer focus group “research†that goes into those cute Cialis TV commercials?